Navrogen Closes $3.0M Seed Financing To Advance Its Preclinical Pipeline Targeting Humoral Immunosuppressed Cancers And Immune-Related Disorders

08/09/21 Navrogen, Inc., a privately held preclinical biotechnology company, announced today that it has raised $3.0M¬†from an equity financing to support its Humoral Immuno-Oncology (HIO) discovery platform and preclinical therapeutic pipeline activities. HIO is a process by which tumors produce factors that suppress a patient’s humoral immune response against malignant tissues.

Read More >